

1ABSTRACT

2**Objectives:** The purpose of this study was the evaluation of any alterations in the
3microvascular network of the nasal mucosa in patients with pulmonary sarcoidosis
4and the investigation of potential correlations with olfactory acuity and serum levels
5of angiotensin-converting enzyme (sACE).

6**Design:** Patients' nasal mucosa was examined with contact endoscopy (CE). A novel
7classification scheme for the microvascular pattern at the anterior septal mucosa
8(Little's area) was introduced and implemented. Olfaction was tested using
9sniffin'sticks. Fifteen healthy subjects served as controls.

10**Participants:** 15 patients with pulmonary sarcoidosis and sinonasal symptoms.

11**Main outcome measures:** Microvascular pattern at the anterior septal mucosa
12(Little's area). Olfaction tested using sniffin'sticks.

13**Setting: Tertiary referral medical centre.**

14**Results:** The nasal microvascular network was disrupted under CE in most (14/15)
15patients, while in one patient no microvascular net could be detected. Moreover,
16hyposmia was documented in four patients and complete anosmia in one patient. In
17healthy subjects, a very strong correlation between vascular pattern of the mucosa and
18olfactory test results was found ($r=0.93$).

19**Conclusions:** Contact endoscopy findings show promise and should be further
20tested, to evaluate their validity as a surrogate marker of mucosal nasal inflammation
21in sarcoidosis patients with sinonasal symptoms. Vascular patterns of nasal mucosa
22and olfaction seem to be strong correlated.

23**Keywords:** sarcoidosis; pulmonary; nasal; microvascular; contact endoscopy; sniffin'
24sticks

25**Keypoints**

- 26 • Changes in the microvascular network of the nasal mucosa can be
27 accompanied by changes in olfaction.
- 28 • The lack of a special classification of microvascular patterns of the nasal
29 mucosa has led us to the introduction and use of a modified version of the
30 Negoro's classification.
- 31 • . A major future research challenge is the validation of the use of the vascular
32 patterns of nasal mucosa as a tool to predict nasal (and possibly, also
33 pulmonary) disease activity and treatment response in patients with pulmonary
34 sarcoidosis and symptoms of sino-nasal disease.
- 35 • Contact endoscopy using traditional and novel colorants emerges as a
36 promising procedure for on-site diagnosis of both early and advanced or late
37 inflammatory mucosal spots or generalized mucosal affection in sarcoidosis.
- 38 • The utility of sACE as a diagnostic and prognostic tool is restricted by its
39 rather low sensitivity and specificity.

40

41

42

43

44

451 INTRODUCTION

46 Sarcoidosis is a chronic inflammatory disease, characterized by the formation of non-
47 caseating granulomas. The lungs are affected in 90% of patients [1,2].
48 Extrapulmonary involvement is observed in more than 50% of cases, mainly
49 involving the liver (65%), the bones and joints (33%), the skin (25%), the eyes (25%)
50 and the central nervous system (15%) [1-3].

51 Otorhinolaryngological symptoms are frequent in sarcoidosis, thanks to a predilection
52 for the upper and lower respiratory tract [4-6]. Sinonasal involvement varies widely,
53 from 1% in isolated forms to 15% in pulmonary sarcoidosis [7-9]. Nasal symptoms
54 than not are more often non-specific, with nasal obstruction being the commonest
55 presenting symptom [7,8]. Histologically documented sarcoidosis of the upper
56 respiratory tract (SURT) occurs in approximately 5% of patients [2,3] and diagnosis is
57 predicated on clinical and radiological findings, combined with evidence of non-
58 caseating granulomas on biopsy [10]. Due to the non-specific symptomatology, CT
59 scan of the paranasal sinuses has been recently proposed as the gold standard for
60 SURT diagnosis [11-14].

61 Our aim was to evaluate the potential pathological microvascular network alterations
62 within the nasal mucosa and any concomitant deterioration in olfactory acuity in
63 sarcoidosis patients with sinonasal symptoms. We have also investigated for
64 correlations between the observed microvascular patterns and potential olfaction
65 defects and serum ACE (sACE) levels.

66

67

68

692 MATERIALS AND METHODS

702.1 Study design

71 We analyzed retrospectively the cases of patients with pulmonary sarcoidosis,
72 referred to our ENT Clinic by the treating pulmonologist for evaluation of symptoms
73 of sinonasal disease between January 2017 and December 2019.

74 All subjects gave written informed consent prior to the study. According to the Greek
75 legislation, an Ethic Committee approval was not required due to the retrospective
76 design of our investigation and the pseudonymization of patient data. All of them
77 were treated according to the guidelines for Management of sarcoidosis in clinical
78 practice, as also reported in previous studies [3,4].

79

80

81

822.2 Subjects

83 Fifteen white patients (6 males and 9 females, Group A), with a mean age of 44.3
84 ($SD=\pm 4.86$) years, sinonasal symptoms and previously histologically proven
85 diagnosis of pulmonary sarcoidosis (typical granulomatous inflammation in tissue
86 biopsy), were included in our study. The foremost frequent signs in physical
87 examination were nasal polyps, epistaxis and nasal crusts. All of the patients had been
88 previously investigated with a CT scan of the paranasal sinuses, revealing findings of
89 chronic sinus inflammation, with mucosal thickening and opacification of one or more
90 sinuses, in all of the cases. The involvement of the maxillary and the ethmoid sinuses
91 was more frequent than the involvement of the frontal sinus. None of the patients
92 showed signs or symptoms of acute Sarcoidosis (Lofgren's syndrome). All patients
93 were under treatment with systemic (oral) corticosteroids, with a mean duration of

94corticosteroid treatment of 4.2 ± 2.2 years. All the patients, because of nasal congestion
95and crusting, were receiving intranasal corticosteroids (mometasone, as nasal spray,
96dose: twice per day) at the time of the examination. Patients' baseline characteristics
97are presented in **Table 1**. Fifteen healthy subjects (6 males and 9 females, **Group B**),
98with mean age 45.5 years ($SD = \pm 6.66$ years) were also studied.

99Bearing in mind that, such diseases as primary biliary cirrhosis, alcoholic liver
100disease, hyperparathyroidism, hyperthyroidism, diabetes mellitus, multiple myeloma,
101amyloidosis, Gaucher's disease or leprosy, may cause higher levels of ACE, these
102conditions have been used as exclusion-criteria. Patients' findings were also
103compared to those of 15 healthy volunteers, which served as a control group. The data
104of those patients have been chosen randomly from a data base, used for previous
105studies of ours [15-17].

106**2.3 Examination Methods-Contact Endoscopy**

107Conventional fiber optic endoscopy, contact endoscopy, and olfaction test were all
108first performed by two of the authors (P.P and G.K), blinded for the underlying
109condition, with a contact endoscope (Karl Storz, 7215AA, 0° , 23 cm long, 4 mm in
110diameter; Tuttlingen, Germany) as an outpatient procedure. A standardized technique
111was employed in each patient. A contact endoscope (CE) was connected to a 150W
112xenon light source, a video camera, and an SVHS video recorder (Olympus, nCare
113medical recorder). The endoscope was slowly inserted through the nasal cavity to the
114nasopharynx, which was assessed for any abnormality. All findings were recorded
115digitally. All endoscopies and recordings were performed by an investigator blinded
116to the condition of the patients. A second examiner reached in all cases the same

117conclusion. All pictures taken, came from the Little's area, where the vesicles more
118simple to be detected because of the Kiesselbach's plexus.

119After careful suction of secretions, the anterior part of the nasal cavity was stained
120with methylene blue 1%. Then the mucosa was gently touched with the tip of the
121contact endoscope.. The whole procedure, including both sides of the nasal cavity,
122lasted between 5- and 10-min.

123To our knowledge, there has not been any standardized scale describing the
124morphology of the blood vessels of the nasal mucosa to date. Based on previous
125experience and studies on the morphology and vascularization of the oral mucosa
126[18], we decided to use a modification of Negoro's classification for the description of
127the microvascular patterns of the nasal mucosa. Based on the accessibility of the
128Kiesselbach's area at the anterior septal mucosa that comprises four arterial
129anastomoses, therefore very easy to identify and describe with the use of the contact
130endoscope, the authors have chosen to modify and apply Negoro's Classification for
131the characterization of vascular morphology of nasal mucosa [17]. This classification
132describes with great accuracy the different vascular patterns [17]. According to the
133modified Negoro's Classification, there are 5 morphological types of nasal mucosa
134vascularization: **Type A** (clear loop and wooden branch shape), **Type B** (unclear loop
135and wooden branch shape), **Type C** (elongated blood vessels), **Type D** (granular
136shape or dotted shape) and **Type E** (unclear blood vessels). Type A represents the
137"healthiest" morphology and Type E corresponds to the "most pathological"
138morphology.

139

1402.4 Sniffin' Sticks Test

141 For odor presentation, the cap was removed from the pen for approximately 3s, the
142 pen's tip was brought in front of the patient's nose and thoroughly moved from left to
143 right nostril and backwards. Individual scores can be related to standard values for (a)
144 normosmia (normal olfactory function), (b) hyposmia (impaired olfactory function) or
145 (c) functional anosmia (residual or absent olfactory function) [18].

146

147 **2.5 Statistical analysis**

148 The null hypothesis is that there is no correlation between the different microvascular
149 patterns and the olfactory results or the sACE-levels. The results of Sniffin' Sticks
150 have also been compared. To test if the recorded values were normally distributed,
151 we applied a quantile-quantile plot (QQ plot), which proved that the distribution was
152 not normal. As a result, non-parametric tests were applied. The level of statistical
153 significance was set at $p < 0.05$. On each occasion, the findings between two groups
154 were compared by using Kruskal-Wallis and Mann-Whitney tests. The Bonferroni
155 correction was applied when necessary. Tukey's multiple comparison was used to
156 detect differences significant at the 0.05-level in mean thresholds for both groups.

157 For analysis of the regression between smell tests and vascularization of the nasal
158 mucosa, the Kendall rank correlation coefficient was applied. Kendall's tau measures
159 the strength of the relationship between the two variables, assessing values between
160 minus one and plus one. A positive correlation signifies that the ranks of both the
161 variables are increasing, whereas a negative correlation signifies that as the rank of
162 one variable is increased, the rank of the other variable is decreased. The null
163 hypothesis was that the two variables examined on each occasion were independent.

164The results were analyzed using SPSS software (Version 12 for Windows, SPSS Inc.
165Chicago, IL, USA).

166

1673 RESULTS

168Based on the findings obtained from the control group, contact endoscopy allowed us
169to identify squamous epithelium, ciliated epithelium, glandular ostia, mucus, and sub-
170mucosal vascular network. Squamous epithelium was usually present in the anterior
171tip and inferior border of the lower turbinate, and in the anterior septum and vestibule.
172Displacing the contact endoscope, ciliated epithelium was visible in the rest of the
173inferior turbinate and in other areas of the nasal cavity.

174By using contact endoscopy, we also managed to observe the condition of the
175microvascular network correlated to the damage of the nasal mucosa. More
176specifically, 4 patients (27 %) had a **Type C** microvascular network pattern
177(elongated blood vessels), 10 patients (67%) had a **Type D** pattern (granular or dotted
178shape) and only 1 patient a **Type E** pattern (absence of any definitive vascular net). In
179the control group, 8 healthy (53%) subjects showed a **Type A**, and the rest 7 patients
180(47%) a **Type B** pattern. No septum perforation was observed in any subject of the
181study group. **Pictures 1A and 1B** depict the subject's septum's nasal mucosa, in
182comparison with normal findings of a subject from the control group that are
183presented in **Picture 2**.

184With the use of the Sniffin' sticks we observed normosmia in the majority of the
185patients (n=10), hyposmia in other 4 patients (3 patients have identified 11 out of 16
186odors and 1 patient 12 odours) and only 1 patient was found with anosmia (3 out of 16
187odors identified). Interestingly, the 4 patients suffering from hyposmia had a **Type D**

188vascular pattern, and the patient with anosmia has a **Type E** pattern. In this latter
189patient no pathological findings regarding microvascular structures were observed,
190either disrupted or diminished, apart from extremely edematous and friable mucosa. It
191should be also stressed, that all these patients suffering from olfaction disorders were
192not diagnosed with nasal polyps. All subjects of the control group showed a
193normosmia. Our findings are presented in detail on **Table 2**.

194The application of Kendall's - tau criterion between the vascular pattern and the
195Sniffin' Sticks test results showed only a weak correlation for the patients of Group A
196($r=0.2$). Stronger correlations have been found between vascularization patterns and
197sACE-levels, as well as sACE levels and the results of the olfactory test ($r=0.3$ and
198 $r=0.4$, respectively). Interestingly, in healthy subjects a strong correlation between
199vascularization of the mucosa and olfactory test results was found ($r=0.93$).

200Another interesting finding is the lack of direct association of ACE levels with
201olfaction. As depicted in Tables 1 and 2, the levels of sACE in patients suffering from
202hyposmia range between 34 and 189 nmol/mL. By the anosmic patient the level of
203sACE was estimated at 36 nmol/mL.

204

2054 **DISCUSSION**

206In this study we demonstrated, that patients with sarcoidosis and sinonasal symptoms
207display significant alterations in the nasal mucosa, both macroscopic (crusts,
208necrotized tissue) and microscopic (disturbed microvascular patterns). We also
209showed that the latter finding may also be combined with a reduced olfactory acuity,
210or, in some patients, with complete absence of it. On the other hand, it has been
211shown that in healthy subjects a strong correlation exists between vascularization of

212the mucosa and olfactory acuity. Till now, there is not enough data correlating the
213degree of the inflammation or alterations of the mucosa to the presence of
214microvascularization.

215The lack of a special classification of the microvascular patterns of the nasal mucosa
216has led us to the introduction and use of a modified version of the Negoro's
217classification [17]. This classification has been previously successfully applied to
218describe alterations oral mucosa [15-17]. However, we did not use it aiming to
219explain any morphological variations, such as those of the mucosa's surface, but
220rather as an adjunctive tool in our attempt to provide a more accurate classification of
221the vascular network patterns, in both patients and healthy subjects. To our knowledge
222this is the first time that such an approach has been attempted.

223The relative variability in the microvascular pattern observed in the group of healthy
224subjects deserves attention, as although they were never smokers, receiving intranasal
225medication and no medical history suggestive of sinonasal disease, they had displayed
226two different vascular patterns (**Type A** and **B**).

227In case of chronic inflammation of the nasal mucosa, the cellular turnover is
228accelerated allowing the presence of less mature cells at the superficial layers [20,21].
229The latter finding could explain the unclear microvascular net or even its lack in some
230of our patients. To our knowledge, the present study is one of the very few, if not the
231only one, to provide such information.

232Another interesting finding of our study is the fact that 5 of the patients had impaired
233olfaction (4 with hyposmia, 1 with anosmia). These findings are in accordance with
234those reported in a previous study, in which the authors suggest that the coexistence

235of chronic rhinosinusitis and the presence of at least 2 of the signs of nasal crusting,
236anosmia, or epistaxis are highly specific for sarcoid rhinosinusitis [5].

237

238We have also investigated the potential correlation of sACE levels to vascularization
239of the nasal mucosa. Interestingly, a modest correlation between microvascular
240pattern on CE and sACE levels ($r=0,3$) was found. Although 30–80% of sarcoidosis
241patients have increased sACE levels with sensitivity ranging between 22% and 86%
242and specificity between 54% and 95% [22-23], we found no other study correlating
243sACE-levels to the severity of otolaryngological findings. ACE is an acid
244glycoprotein that converts angiotensin I into angiotensin II, produced by lung
245endothelial cells, mainly activated alveolar macrophages [19,20]. However, its utility
246as a diagnostic and prognostic tool is restricted by its rather low sensitivity and
247specificity [21-24] as it may be elevated in other granulomatous disorders (such as
248tuberculosis, borelliosis, histoplasmosis, Gaucher's disease, silicosis),
249hyperthyroidism, diabetes, and other diseases [24,25].

250Our study has a few limitations. Patients were already under at the time of evaluation,
251therefore, our findings may have been affected by treatment with corticosteroid
252therapy, both systematically and locally. Furthermore, the retrospective analysis of
253their data did not allow the evaluation of microvascular patterns of the mucosa before
254and after treatment. Nonetheless, the evaluation (CE, Sniffin Sticks) was rather done
255prospectively. Another limitation of our study is its small sample size, however the
256relative rarity of the sinonasal involvement in pulmonary sarcoidosis should be
257considered. To ensure more valid comparisons between changes in the nasal mucosal
258microvascular network and olfaction, particularly in the different stages of the
259disease, a larger longitudinal prospective study should follow, that may allow the

260establishment of vascular robust patterns, as well as the evaluation of treatment
261effectiveness on the associated sino-nasal symptoms in pulmonary sarcoidosis.
262Finally, we have not investigated nasal vascular morphology in sarcoidosis patients
263without nasal symptoms, because this was not possible at the time of drafting the
264protocol This could be a matter of further investigation.

2655 CONCLUSIONS

266In conclusion, our findings suggest that changes in the microvascular network of the
267nasal mucosa may be used as a surrogate marker of pulmonary sarcoidosis. These
268changes may also be accompanied by changes in olfaction. This is further supported
269by the very strong correlation between vascular pattern of the mucosa and olfactory
270test results in healthy individuals.

271A major future research challenge is the validation of the use of the vascular patterns
272of nasal mucosa on CE as a tool to predict nasal (and possibly, also pulmonary)
273disease activity and treatment response in patients with pulmonary sarcoidosis and
274symptoms of sino-nasal disease.

275

276

277

278

279LEGENDS

280**TABLE 1.** Clinical characteristics of the 15 patients with biopsy proven sinonasal
281sarcoidosis, participating in the study. Abbreviations: CT, computed tomography,
282MSB: maxillary sinus bilateral; ES, ethmoidal sinus; ESB: ethmoidal sinus bilateral;

283FS: frontal sinus, F: Female, M: Male, OCS: Oral steroids, INS: Intranasal steroids.

284The normal range for ACE is less than 40 nmol/mL/min.

285

286**TABLE 2.** Findings on conventional fiber optic endonasal endoscopy, contact
287endoscopy and Sniffin' Sticks test of the study participants. **N=normosmia,**
288**H=hyposmia, A=anosmia.**

289

290**PICTURE 1A.** The picture depicts the microvascular network of a female patient (age
29148), suffering from nasal sarcoidosis during the last 5 years. The vesicles seem to
292have an unclear form, they are rather thin and disrupted.

293**PICTURE 1B.** The mucosa of the same patients seen macroscopically. The mucosa is
294obviously necrotized in multiple regions (the septum and under the turbinate).

295**PICTURE 2.** The vascularization of nasal mucosa (septum) in a healthy subject of
296the control group.

297

298**Data availability**

299The data that support the findings of this study are available from the corresponding
300author upon reasonable request.

301**References**

- 302 1. Kunitake R , Kuwano K, Miyazaki H, Hagimoto N, Nomoto Y, Hara N.
303 Apoptosis in the course of granulomatous inflammation in pulmonary
304 sarcoidosis. Eur Respir J. 1999;13(6):1329-1337.

- 305 2. Coup AJ, Hopper IP. Granulomatous lesions in nasal biopsies. *Histopathology*
306 1980;4(3):293-308.
- 307 3. Baughman RP, Lower EE, du Bois RM. Sarcoidosis. *Lancet*. 2003;
308 361(9363):1111–1118.
- 309 4. Baughman RP, Lower EE, Tami T. Upper airway. 4: Sarcoidosis of the upper
310 respiratory tract (SURT). *Thorax*. 2010;65(2):181-186.
- 311 5. Fergie N, Jones NS, Havlat MF. The nasal manifestations of sarcoidosis: a
312 review and report of eight cases. *The Journal of Laryngology and Otology*.
313 1999; 113:893-898. *J Laryngol Otol*. 1999;113(10):893-898.
- 314 6. Dessouky O. Isolated sinonasal sarcoidosis with intracranial extension: case
315 report. *Acta Otorhinolaryngol Ital*. 2008;28(6):306.
- 316 7. Ozdoğan A, Acioğlu E, Karaman E, Oz B, Müsellim B. A difficult case:
317 sarcoidosis of the middle ear. *Am J Otolaryngol*. 2009;30(4):281-284.
- 318 8. Frederiksen LG, Jørgensen K. Sarcoidosis of the nose treated with laser
319 surgery. *Rhinology*. 1996; 34(4):245-246.
- 320 9. Damuth TE, Bower JS, Cho K, Dantzker DR. Major pulmonary artery stenosis
321 causing pulmonary hypertension in sarcoidosis. *Chest*. 1980; 78(6):888-891.
- 322 10. Whittemore KR, Jr., Dargie JM, Lally T. Sarcoidosis of the pinnae in a 17-
323 year-old. *Am J Otolaryngol*. 2012; 33(5):631-633.
- 324 11. Mortaz E, Adcock IM, Barnes PJ. Sarcoidosis: Role of non-tuberculosis
325 mycobacteria and *Mycobacterium tuberculosis*. *International Journal of*
326 *Mycobacteriology*. 2014; 3(4):225-229.

- 327 12. Cardona PJ. Reactivation or reinfection in adult tuberculosis: Is that the
328 question? *International Journal of Mycobacteriology*. 2016;5(4):400-407.
- 329 13. Krespi YP, Kuriloff DB, Aner M. Sarcoidosis of the sinonasal tract: a new
330 staging system. *Otolaryngol-Head and Neck Surg*. 1995;112(2):221-227.
- 331 14. Kirsten AM, Watz H, and Kirsten D. Sarcoidosis with involvement of the
332 paranasal sinuses - a retrospective analysis of 12 biopsy-proven cases. *BMC*
333 *Pulm Med*. 2013; 13: 59. Pavlidis P, Gouveris H, Gorgulla H, Hast HJ, Maurer
334 J. Electrogustometry and contact endoscopic findings in patients with head
335 and neck malignancies treated with chemotherapy, radiotherapy or
336 radiochemotherapy. *Chem Senses*. 2015; 40(3):165-1671.
- 337 15. Pavlidis P, Cámara RJA, Kekes G, Gouveris H. Bilateral taste disorders in
338 patients with Ramsay Hunt syndrome and Bell palsy. *Ann Neurol*. 2018;
339 83(4):807-815.
- 340 16. Pavlidis P, Gouveris H, Kekes G. Electrogustometry Thresholds, Tongue Tip
341 Vascularization, Density, and Form of the Fungiform Papillae Following
342 Smoking Cessation. *Chem Senses*. 2017; 42(5):419-23.
- 343
- 344 17. Negoro A, Umemoto M, Fukazawa K, et al. Observation of tongue papillae
345 by video microscopy and contact endoscopy to investigate their correlation
346 with taste function. *Auris Nasus Larynx*. 2004; 31(3):255-259.
- 347 18. Valeyre D, Prasse A, Nunes H, et al. Sarcoidosis. *Lancet*. 2014;
348 383(9923):1155–1167.

- 349 19. Schriever V, Croy I, Haehner, A, Hummel T. Updated Sniffin' Sticks
350 normative data based on an extended sample of 9139 subjects. Archives of
351 Oto-Rhino-Laryngology. 2019;276:719-728.
- 352 20. Duchemann B, Lavolé A, Naccache J-M, Nunes, et al. Laryngeal sarcoidosis:
353 a case-control study. Sarcoidosis Vasc Diffuse Lung Dis. 2014;31(3):227-34.
- 354 21. Aubart FC, Ouayoun M, Brauner M, et al. Sinonasal involvement in
355 sarcoidosis: a case-control study of 20 patients. Medicine. 2006; 85(6):365-
356 371.
- 357 22. Braun JJ, Gentine A, Pauli G. Sinonasal sarcoidosis: review and report of
358 fifteen cases. Laryngoscope. 2004; 114(11):1960-1963.
- 359
- 360 23. Nakamura Y, Takeda T, Ishii M, et al. Elevation of serum angiotensin-
361 converting enzyme activity in patients with hyperthyroidism. J Clin
362 Endocrinol Metab. 1982; 55(5): 931–934.
- 363 24. Zorn SK, C. Stevens A, Schachter EN, Gee JB. The angiotensin converting
364 enzyme in pulmonary sarcoidosis and the relative diagnostic value of serum
365 lysozyme. Lung. 1980; 157(2): 87–94.
- 366 25. Gulati S, Krossnes B, Olofsson J, Danielsen A. Sinonasal involvement in
367 sarcoidosis: a report of seven cases and review of literature. Eur Arch
368 Otorhinolaryngol 2012; 269(3):891-896.
- 369
- 370